Fulgent Genetics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Fulgent Genetics wird ein jährliches Gewinn- und Umsatzwachstum von 39.3% bzw. 9.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 42.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -1.4% betragen.

Wichtige Informationen

39.3%

Wachstumsrate der Gewinne

42.1%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	28.1%
Wachstumsrate der Einnahmen	9.8%
Zukünftige Eigenkapitalrendite	-1.4%
Analystenabdeckung	Low
Zuletzt aktualisiert	05 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BMV:FLGT * - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	361	-54	N/A	N/A	3
12/31/2025	322	-62	N/A	N/A	3
12/31/2024	282	-58	N/A	N/A	3
6/30/2024	291	-163	12	37	N/A
3/31/2024	288	-166	18	42	N/A
12/31/2023	289	-168	5	27	N/A
9/30/2023	286	-64	21	45	N/A
6/30/2023	307	-49	31	56	N/A
3/31/2023	365	-26	42	57	N/A
12/31/2022	619	143	235	254	N/A
9/30/2022	803	272	277	297	N/A
6/30/2022	925	392	411	429	N/A
3/31/2022	953	461	476	494	N/A
12/31/2021	993	507	515	539	N/A
9/30/2021	1,036	569	554	596	N/A
6/30/2021	910	493	405	453	N/A
3/31/2021	773	417	327	372	N/A
12/31/2020	422	214	105	141	N/A
9/30/2020	135	48	-6	6	N/A
6/30/2020	44	3	-1	1	N/A
3/31/2020	35	0	4	6	N/A
12/31/2019	33	0	4	6	N/A
9/30/2019	30	-2	6	6	N/A
6/30/2019	25	-4	1	2	N/A
3/31/2019	22	-6	0	2	N/A
12/31/2018	21	-6	-4	-1	N/A
9/30/2018	20	-5	-7	-3	N/A
6/30/2018	19	-6	-8	-2	N/A
3/31/2018	18	-5	N/A	-1	N/A
12/31/2017	19	-3	N/A	1	N/A
9/30/2017	20	0	N/A	4	N/A
6/30/2017	21	-5	N/A	4	N/A
3/31/2017	20	-13	N/A	5	N/A
12/31/2016	18	-14	N/A	4	N/A
9/30/2016	15	-22	N/A	3	N/A
6/30/2016	13	-15	N/A	2	N/A
3/31/2016	11	-6	N/A	0	N/A
12/31/2015	10	-5	N/A	-1	N/A
12/31/2014	1	-1	N/A	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: FLGT * wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: FLGT * wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: FLGT * wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: FLGT *Die Einnahmen des Unternehmens (9.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt MX (7% pro Jahr).

Hohe Wachstumseinnahmen: FLGT *Die Einnahmen des Unternehmens (9.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: FLGT * wird voraussichtlich in 3 Jahren unrentabel sein.

Fulgent Genetics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Fulgent Genetics, Inc. Revises Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023

Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023

Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022

Recent updates

Chief Financial Officer recently sold Mex$729k worth of stock

Chairman & CEO recently sold Mex$1.0m worth of stock

Second quarter 2024 earnings released: US$0.29 loss per share (vs US$0.38 loss in 2Q 2023)

Fulgent Genetics, Inc. Revises Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. to Report Q2, 2024 Results on Aug 02, 2024

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.52 loss in 1Q 2023)

Fulgent Genetics, Inc. to Report Q1, 2024 Results on May 03, 2024

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$5.64 loss per share (vs US$4.77 profit in FY 2022)

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Third quarter 2023 earnings released: US$0.44 loss per share (vs US$0.057 profit in 3Q 2022)

Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting

Fulgent Genetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Chief Financial Officer recently sold Mex$5.8m worth of stock

Chief Financial Officer recently sold Mex$1.0m worth of stock

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023

Fulgent Genetics, Inc. Announces Data from a Phase 1/1b Clinical Study of FID-007 in Treating Various Solid Tancers

COO & President recently sold Mex$824k worth of stock

First quarter 2023 earnings released: US$0.52 loss per share (vs US$5.09 profit in 1Q 2022)

Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023

Less than half of directors are independent

Fulgent Genetics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Less than half of directors are independent

COO & President recently sold Mex$457k worth of stock

Less than half of directors are independent

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquire Fulgent Pharma Holdings, Inc for approximately $100 million.

Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022

Fulgent Genetics, Inc. Announces Resignation of Leonard Post from the Board and as the Chair of the Nominating and Corporate Governance Committee

The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Fulgent Genetics, Inc

Fulgent Genetics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Less than half of directors are independent

Less than half of directors are independent

Fulgent Genetics, Inc. Announces Resignation of John Bolger from the Board

Pomerantz Law Firm Announces the Filing of A Class Action Against Fulgent Genetics, Inc

Chief Financial Officer recently sold Mex$552k worth of stock

COO & President recently sold Mex$599k worth of stock

Investor sentiment deteriorated over the past week

Chief Financial Officer recently sold Mex$1.9m worth of stock

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2022

Second quarter 2022 earnings released: EPS: US$0.38 (vs US$2.74 in 2Q 2021)

Fulgent Genetics, Inc. Announces Launch of PCR Based Test to Detect Monkeypox

Investor sentiment improved over the past week

Fulgent Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Helio Genomics and Fulgent Genetics Announces That American Medical Association Approves A New Category I Cpt® Code for the Helioliver™ Test

COO & President recently sold Mex$719k worth of stock

COO & President recently sold Mex$719k worth of stock

Chief Financial Officer recently sold Mex$1.3m worth of stock

First quarter 2022 earnings released: EPS: US$5.09 (vs US$6.96 in 1Q 2021)

Fulgent Genetics, Inc. Provides Earning Guidance for Second Quarter of 2022

Fulgent Genetics, Inc. Announces Executive Appointments

Fulgent Genetics, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2022 and Full Year Ended December 31, 2022

Fulgent Genetics, Inc., Annual General Meeting, May 18, 2022

Chief Financial Officer recently sold Mex$530k worth of stock

Chief Financial Officer recently sold Mex$530k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Fulgent Genetics, Inc. Provides Earning Guidance for the First Quarter and Full Year of 2022

Fulgent Genetics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Investor sentiment deteriorated over the past week

Chief Financial Officer recently sold Mex$1.1m worth of stock

Investor sentiment deteriorated over the past week

Chief Operating Officer recently sold Mex$1.3m worth of stock

Chief Operating Officer recently sold Mex$2.4m worth of stock

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$4.13 (vs US$2.11 in 3Q 2020)

Chief Financial Officer recently sold Mex$1.1m worth of stock